UK Clinical Vaccine Network Conference 2022

Bringing together and showcasing the work of the UK clinical vaccine community, to facilitate co-operation and collaborate on future challenges.

Register now

It is with great excitement that we can announce this year’s Clinical Vaccine Network Conference will be held in person at the Royal College of Physicians, London.

Hosted on the 30th June, this event will cover a wide spectrum of issues in vaccine development, presentations on the latest research, and the future of vaccines.

Whilst this conference will be made available to join virtually we thoroughly recommend attending in person to not miss out on this excellent networking opportunity. There will be an array of UK healthcare professionals, and other relevant decision makers who have a specific interest in vaccine intervention in the patient pathway.

Please share the flyer for the event available here with your colleagues.

If you have any queries, or would like to enquire about sponsorship of this event, please contact:


Seqirus has sponsored this conference but has had no input into the arrangements or the content except the session on “Improving Influenza Vaccine Uptake” which has specifically been sponsored and arranged by Seqirus.

To view the recordings from the online UK Clinical Vaccine Network Conference held in 2020 please click here Clinical Vaccines Network Virtual Conference 2020

Professor Kirsty Le Doare

I am a Professor of Vaccinology and Immunology and chief investigator for SGUL@MUJHU maternal vaccine and seroepidemiology studies. I am the chair of the DNDi maternal and neonatal health COVID19 research coalition and is a WHO scientific advisor for maternal vaccination. My group want to understand why some babies get very ill and die from infections in the first months of life and how we can harness protection transferred from mother to her baby via the placenta and in breastmilk. My groups in Uganda and the UK use a variety of approaches to study GBS and other neonatal pathogens such as E. coli and Klebsiella, ranging from clinical studies and whole genome sequencing, to in vitro and in vivo models and complex immunology.